Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ti-061
- Development stage
- Unknown
- Lead developer
- Arch Oncology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ti-061 is an investigational humanized IgG4 monoclonal antibody targeting CD47, a cell-surface protein that acts as a "don't eat me" signal to the immune system. By binding to CD47, Ti-061 blocks its interaction with SIRPα on macrophages, thereby promoting the phagocytosis of cancer cells. Developed by Tioma Therapeutics (later Arch Oncology), the drug was designed as an innate immune checkpoint inhibitor for the treatment of advanced solid tumors. Clinical development included a Phase 1/2 study in the United Kingdom evaluating Ti-061 as both a monotherapy and in combination with the PD-1 inhibitor pembrolizumab; however, the trial was prematurely terminated in 2017.
02
Targets
CD47 (Cluster of Differentiation 47)
Beyond the preview
Go deeper on Ti-061.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ti-061.